Julie Vose, MD, MBA, and Rafat Abonour, MD, on Multiple Myeloma: The Path to a Cure
2015 ASH Annual MeetingJulie Vose, MD, MBA, of the University of Nebraska Medical Center, and Rafat Abonour, MD, of Indiana University Simon Cancer Center, discuss the session that he chaired on the question of whether researchers can design therapy that addresses the heterogeneity of the disease and eradicate most if not all of the myeloma clones.
Related Videos
Sagar Lonial, MD, and Torben Plesner, MD, on Multiple Myeloma: Updated Results of the Phase I/II GEN503 Study
Sagar Lonial, MD, of Emory University School of Medicine, and Torben Plesner, MD, of Vejle Hospital, discuss the latest findings on the use of daratumumab in combi...
David Henry, MD, on Multiple Myeloma: Expert Perspective
David Henry, MD, of Pennsylvania Hospital, discusses the exciting developments in multiple myeloma treatment, including the three new drugs approved for the disease in November 201...
Richard M. Stone, MD, on AML: Results of the RATIFY Trial
Richard M. Stone, MD, of the Dana-Farber Cancer Institute, discusses this international prospective study on the survival impact of midostaurin, a multikinase inhibitor, in newly d...
James N. Kochenderfer, MD, on Multiple Myeloma: Results of a First-in-Humans Clinical Trial
James N. Kochenderfer, MD, of the National Cancer Institute, reports on remissions of multiple myeloma during a trial of T cells expressing an anti-B-cell maturation antigen chimer...
David A. Williams, MD, on the Goals and Highlights of ASH 2015
Outgoing ASH President, David A. Williams, MD, of the Dana-Farber/Boston Children’s Hospital, gives an overview of this year’s Annual Meeting of the American Society of Hematology....
